GERD 2003 – A Consensus on the Way Ahead
Open Access
- 1 March 2003
- journal article
- review article
- Published by S. Karger AG in Digestion
- Vol. 67 (3) , 111-117
- https://doi.org/10.1159/000071290
Abstract
Gastroesophageal reflux disease (GERD) has in recent times become an important public health issue owing to the considerable health care resources utilized in its management, its deleterious effect on quality of life and the increasing prevalence of a relatively rare complication of reflux disease – esophageal adenocarcinoma. We review here the major current challenges in the field of reflux disease and its complications, and provide some approaches that may be useful in management. The issues to be faced include the very limited comprehension of the reasons behind the increasing prevalence of the disease, difficulties in correlating symptoms with objective data of pathological gastroesophageal reflux and the relatively unsophisticated tools we are employing to investigate the underlying pathophysiology. It is certain that the lack of well-defined and characterized methodologies to compare the effects of therapy require the development of more effective questionnaire-type analytic tools. In regard to treatment, there is little doubt that the widely prescribed proton pump inhibitors have dose-equivalent efficacy and are the most highly effective agents capable of suppressing acid, controlling many of the symptoms of GERD and healing erosions. Nevertheless, many patients continue to experience symptoms on withdrawal or at night. Pharmacological agents that can effectively increase lower esophageal sphincter pressure or promote motility are as yet unavailable. Although the introduction of laparoscopic techniques has resulted in a modest revival in surgical intervention using a variety of ‘wrap-type’ operations, the indications are few and the procedure is associated with a significant morbidity and even mortality especially if the expertise of the surgeon is an issue. Endoscopic techniques of regulating reflux are at this time experimental and not applicable to the general population. Intestinal metaplasia in the lower esophagus is probably very common. Whether and how to, first, screen for, and then, perform surveillance in Barrett’s esophagus remains highly problematic and contentious.Keywords
This publication has 7 references indexed in Scilit:
- Comparable Efficacy of Pantoprazole and Omeprazole in Patients with Moderate to Severe Reflux EsophagitisDigestion, 2003
- Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 monthsEuropean Journal of Gastroenterology & Hepatology, 2002
- The Clinical Importance of Proton Pump Inhibitor PharmacokineticsDigestion, 2002
- Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitisAmerican Journal of Gastroenterology, 2002
- Symptoms Associated with Gastroesophageal Reflux DiseaseDigestive Diseases and Sciences, 2001
- Endoscopy-negative reflux diseaseBest Practice & Research Clinical Gastroenterology, 2000
- Atrophic Gastritis andHelicobacter pyloriInfection in Patients with Reflux Esophagitis Treated with Omeprazole or FundoplicationNew England Journal of Medicine, 1996